Who is Jessie J's partner? Everything you need to know
The singer took to her Instagram page to share the devastating news, telling fans the cancer is still in its early stages and confirming she will undergo surgery in the near future.
The Price Tag singer said she plans on undergoing the surgery following her performance at this month's Summertime Ball at Wembley Stadium and joked it was a 'dramatic way' to get a boob job as she attempted to put on a brave face.
Jessie J is a mum and in a long term relationship with boyfriend Chanan Safir Colman, who is understood to be supporting her through this time.
Here is all we know about him:
Born in Denmark, Colman is a now retired former professional basketball player from the Israel Basketball Premier League.
He was born in 1984 in Gladsaxe, Denmark to an Israeli mother and an American father and grew up there.
In his career he last played for Hapoel Haifa of the Israel Basketball Premier League and before this, played college basketball for Chipola College in Marianna, Florida, before going on to play for professional leagues in Finland, Denmark and now Israel.
He is close to his family and regularly posts on his own social media channels about them.
In September 2022, he shared a photo of his mum on her birthday and wrote: 'You are by far the strongest, most caring, loving and forgiving human being I know.'
Jessie J first went public with her boyfriend Chanan Safir Colman in 2023, but it is believed they were together a while before this date, around 2021 - first meeting just weeks after Jessie J first experienced a miscarriage.
She spoke about her love for Colman after the pair welcomed their first child Sky together May 2023, calling him 'the calm to my crazy,' 'the peace to my fear' and, finally, 'the Daddy to my baby.'
She shared a snap of the pair on her socials and wrote: 'I struggle to keep things private. I think if you know me, you know that. I want to protect people I love and keep it for myself.'
Sky is now two years old.
She continued, 'And then so often I think f--- it because life is short and don't want to regret it. Once you open the door, you can't close it."
She referred to her partner as a 'beam of light' that 'lit up my dark days,' adding that their relationship has been 'a whirlwind love.'
The birth announcement came after Jessie J experienced the miscarriage in November 2021.
'For all of you that have followed my journey to this moment, thank you for all your continued love and support,' she wrote following the birth of her son.
Before finding Colman, Jessie J was in a long term relationship with Hollywood actor Channing Tatum.
She dated the Magic Mike star on and off for around two years, with the pair first linked in October 2018.
They were seen together loved up, but split in December 2019 before getting back together in 2020, but broke up later on.
Before Channing, Jessie J was with fellow singer and R&B star Luke James, with the pair dating from November 2014 to October 2015.
They reportedly met through friends in the music industry and were seen together on numerous occasions during their relationship but kept their love out of the limelight.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
8 minutes ago
- Newsweek
Donald Trump Doubles Down on Mathematically Impossible Drug Price Cuts
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump has doubled down on his claim of reducing drug prices by amounts that are mathematically impossible. Trump told reporters on Sunday that his administration had cut the price of some prescription drugs by as much as 1,500 percent. "Well, one of the things they're going to be talking about pretty soon are the tremendous drop in drug prices. You know, we've cut drug prices by 1,200, 1,300, 1,400, 1,500 percent. I don't mean 50 percent. I mean 14-, 1,500 percent," the president said. When asked to clarify the president's remarks, White House spokesperson Kush Desai told Newsweek, "It's an objective fact that Americans are paying exponentially more for the same exact drugs as people in other developed countries pay, and it's an objective fact that no other Administration has done more to rectify this unfair burden for the American people." Why It Matters Trump's remarks signal a misunderstanding of how pricing and percentages work, which could undermine public confidence in his ability to tackle problems such as drug pricing. President Donald Trump speaks with reporters near Air Force One at the Lehigh Valley International Airport in Allentown, Pennsylvania, on August 3. President Donald Trump speaks with reporters near Air Force One at the Lehigh Valley International Airport in Allentown, Pennsylvania, on August To Know Reducing the price of a drug by 100 percent would make it free, and a reduction greater than 100 percent suggests pharmaceutical companies would pay their customers to take their prescription drugs. Commenting on Trump's claims, Jeffrey Frankel, a professor of capital formation and growth at Harvard University, told Newsweek that the numbers were "indeed mathematically impossible." On Friday, the president made similar claims of bringing drug prices down by "1,000 percent, 1,200 percent" in an interview with Newsmax's Rob Finnerty. That came a day after the White House said Trump had written to the heads of 17 pharmaceutical companies outlining steps they needed to take to bring down the prices of drugs sold in the U.S. to match the lowest price paid by a group of other economically advanced countries. According to a fact sheet the White House released on Thursday, Trump's letters said the pharmaceutical manufacturers' proposals for implementing his May executive order—which seeks to achieve "most favored nation" pricing in the United States—had "fallen short." However, it did not mention the percentage reductions the president has discussed in recent days. What People Are Saying Jeffrey Frankel, a professor of capital formation and growth at Harvard University, told Newsweek: "They are indeed mathematically impossible. If he cut prices 90 percent, the drugs would cost 1/10 as much as before. If 100 percent, then they would cost zero. If cutting 1,000 percent means a thing, then it means that the drug company pays you (a lot) to take the drug." He added: "It's almost as if Trump is making fun of his supporters, seeing what increasingly absurd statements he can get away with." Justin Wolfers, a professor of economics and public policy at the University of Michigan, told Newsweek: "This is not a question for an economist, but rather a sixth grader. After all, the Common Core curriculum standard states that students should know how to 'find a percent of a quantity as a rate per 100 (e.g., 30 percent of a quantity means 30/100 times the quantity).'" Wolfers added: "I just checked with my sixth grader (Oliver Wolfers), and he confirmed that he has studied percentages and that the president's math does not make sense 'because then the prices would be negative.' He added, 'Is he an idiot?' before returning to watching YouTube. Oliver's father agrees with Oliver's mathematical analysis and encourages him to use more positive language when engaging with fellow kids." Pau Pujolas, a professor of economics at McMaster University, told Newsweek: "If your grocery bill is $100 and you get a 50 percent reduction in price, you pay $50. If you get a 75 percent reduction, you pay $25. If you get a 99 percent reduction, you pay $1. If you get a 100 percent reduction, you pay $0. You can't get a reduction larger than that ... so 1,200 percent doesn't make sense. "Talking about bad math: Firing Erika McEntarfer, the director of the Bureau of Labor Statistics (BLS), is way worse than a POTUS not knowing how to operate with basic percentages. Let's not miss the forest for the trees." President Donald Trump said at a Republican dinner in July: "This is something that nobody else can do. We're gonna get the drug prices down—not 30 or 40 percent, which would be great, not 50 or 60 percent. No, we're gonna get them down 1,000 percent, 600 percent, 500 percent, 1,500 percent. Numbers that are not even thought to be achievable." The White House fact sheet said: "From this point forward, President Trump will only accept from drug manufacturers a commitment that provides American families immediate relief from vastly inflated drug prices and an end to the freeriding by European and other developed nations on American innovations." Journalist James Surowiecki wrote on X in response to Trump's comments on Sunday: "It's not just that the math here is nonsensical. It's that Trump hasn't actually cut drug prices yet at all. He's literally just sent letters to drugmakers telling them to cut prices. Does he know that and is lying? Or is he deluded? We have no idea." What Happens Next Trump and the White House have not clarified what he means when he says drug prices will come down by as much as 1,500 percent. The president's letters to pharmaceutical companies give them a 60-day window to present a viable plan to reduce U.S. drug prices.
Medscape
2 hours ago
- Medscape
These Markers May Predict Risk for Bone Loss in SLE
TOPLINE: Osteoporosis was prevalent in 41% of patients with systemic lupus erythematosus (SLE). Factors such as lupus nephritis classes III and IV, U1-ribonucleoprotein (RNP) antibodies, and longer disease duration were associated with lower areal bone mineral density (BMD), and active lupus nephritis was associated with osteoporosis. METHODOLOGY: Researchers analysed data of a subcohort of patients from a prospective observational study to identify factors associated with BMD and the risk for osteoporosis. They included 110 patients with SLE (mean age, 48 years; 92% women) from a hospital in Berlin between July 2015 and January 2022 who fulfilled the American College of Rheumatology/ European League Against Rheumatism 2019 SLE classification criteria and had current or prior glucocorticoid treatment. The analysis included SLE disease activity and a standardised bone health assessment with the DEXA scan and trabecular bone score measurement according to national guidelines. BMD- and osteoporosis-related factors were assessed. The following three co-primary endpoints were assessed: Areal BMD, expressed as the lowest DEXA-derived T score at the lumbar spine (L1-L4), total hip, or femoral neck A composite osteoporosis outcome (a femoral or lumbar spine T score ≤ -2.5 and/or history of a major fragility fracture and/or antiosteoporotic treatment) The prevalence of fragility fractures (any, vertebral, and non-vertebral). TAKEAWAY: Overall, 41% and 35% of patients with SLE had osteoporosis and lupus nephritis, respectively. Factors significantly associated with lower areal BMD included lupus nephritis classes III and IV (P = .025), U1-RNP antibodies (P = .009), higher C-reactive protein levels (P = .015), and longer disease duration (P = .001). Clinical remission (P = .033) and higher Health Assessment Questionnaire scores (P = .009) were positively correlated with areal BMD. Active lupus nephritis was strongly associated with osteoporosis in patients with SLE (odds ratio [OR], 7.42; P = .027), along with other factors such as older age (OR, 1.06; P = .003) and lower Health Assessment Questionnaire scores (OR, 0.29; P = .005). IN PRACTICE: "The identification of SLE-specific risk factors allows us to recognize patients at particular high risk for OP [osteoporosis]. This prompts us to suggest a thorough osteoporosis check-up in patients with high CRP [C-reactive protein], LN [lupus nephritis], or U1-RNP-antibodies," the authors wrote. SOURCE: This study was led by Edgar Wiebe, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Charitéplatz 1, Berlin, Germany. It was published online on July 28, 2025, in Arthritis Research & Therapy. LIMITATIONS: This monocentric cohort study primarily involved White Caucasians, thereby limiting the generalisability of the findings to other patient groups. A potential selection bias may have resulted in overrepresentation of patients with more severe disease courses who were at a high risk for osteoporosis. The cross-sectional design limited the ability to establish causality between identified factors and outcomes. DISCLOSURES: Open access funding was enabled and organised by Projekt DEAL. The prospective observational study received a joint funding from AbbVie, Amgen, Alfasigma, Almirall, Biogen, BMS, Chugai, Fresenius Kabi, Galapagos, GA Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche, Sanofi-Genzyme, and UCB. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Are electric scooters safe? A rash of injuries, deaths raises concerns.
SAN FRANCISCO – A 77-year-old man was killed after being hit by an electric scooter while crossing a street in downtown San Francisco in July, the type of serious scooter-pedestrian collision the city's police department calls 'uncommon.'' Other types of e-scooter accidents that result in a trip to the emergency room, however, are becoming all too frequent across the nation. The growing popularity of electric scooters – easily accessible for commuters to reach their final destination or tourists to enjoy sightseeing – has been accompanied by skyrocketing numbers of injuries, typically to the riders and at times to others in their way. A 2023 report by the Consumer Product Safety Commission revealed that from 2017 – when the devices were first introduced at scale – through 2022, the U.S. recorded 360,800 ER visits related to e-bikes, e-scooters and hoverboards, known collectively as micromobility vehicles. Of those visits, 169,300 were linked to the scooters, or 47%. By comparison, ER trips stemming from e-bike accidents added up to 53,200, or less than 15%. Just as concerning, of the 233 micromobility-related deaths the CPSC registered through that six-year stretch, nearly half (111) were from e-scooter incidents, usually as a result of collisions with cars and/or control issues. Scooters mistakenly seen as 'very low risk' After a dip in the early part of the COVID pandemic, the ER-worthy injuries related to powered scooters – mostly the electric variety – have steadily risen from just under 30,000 in 2020 to 118,485 last year, nearly twice the 2023 total (64,329). 'People view scooters as very, very low risk for some reason, but we do see broken wrists, head injuries, neck injuries, cervical injuries. Those are all very common," said Dr. Eric Cioe-Peña, associate professor of emergency medicine and vice president of Northwell's Center for Global Health in Long Island, New York. Cioe-Peña has noticed the surge in injuries over the last five years, coinciding with the rise in e-scooter ridership. According to data from the National Association of City Transportation Officials, dockless scooter ridership in the U.S. was up to 65 million in 2023, the latest year for which the nonprofit has statistics. As of 2024, there were 130 American cities with e-scooter-sharing programs, the Bureau of Transportation Statistics says. And a recent report projects the North American market for e-bikes and e-scooters to grow from about $500 million last year to more than $3 billion by 2033. Ignoring traffic rules and neglecting protection All those rides will inevitably lead to more injuries, and Cioe-Peña expressed concern about the number or riders who ignore the rules of the road – such as blowing past stop signs – and neglect to wear protective equipment, especially helmets. He said the worst e-scooter injuries he has seen at the ER involved a helmetless rider in Staten Island whose vehicle's front wheel hit an irregular spot on the street – possibly a storm drain slot – and was catapulted over the handlebar. The rider landed on concrete, sustaining a severe concussion and ankle and wrist fractures. 'The pedestrian risk is more sensational," Cioe-Peña said, 'but the real burden of disease is head injuries with unhelmeted riders." Studies of helmet use among e-scooter riders are scarce but generally show low percentages, as little as 2%. Alex Engel, a spokesperson for NACTO, said most of e-scooter injuries are sustained by riders, who are vulnerable to potholes or small objects on the road causing accidents. 'With e-scooters the center of gravity is much higher because you're standing on them, and because the wheels are much smaller and there's in general much less shock (absorption), pavement quality tends to matter a lot more than it does for bikes or e-bikes," Engel said. A need for more safe places to ride Still, he pointed out cars are by far the biggest danger to riders, which makes the significant increase in bike lanes across many cities a welcome development for micromobility fans. 'The most important thing any city can do is providing safe places for people to ride," Engel said. 'That provides space for those who are already riding, and it encourages more ridership. There's safety in numbers.'' Few if any cities have bike lanes on every street, and it's not uncommon to see e-scooters on sidewalks, which is generally against the law. Though civic leaders tend to appreciate the e-scooters' eco-friendly convenience, a few cities and two states – Pennsylvania and Delaware – have effectively banned them from public roads. There's wide variation in state and municipal regulations regarding e-scooters, from minimum age requirements to whether riding on sidewalks is allowed, leading to confusion among practitioners. While more than 30 states have set speed limits of between 15 mph and 20 mph, another six permit riders to go at least as fast as 25 mph, according to a detailed guide on the webpage of scooter maker Unagi. Lax enforcement of regulations The regulations are not commonly known and rarely enforced, said Joseph Schofer, a professor emeritus of civil and environmental engineering at Northwestern University who specializes in transportation issues. 'A teenager riding a scooter, my sense is they have no obligation to get training," Schofer said. 'And if there is, there's no way to enforce it." He remembers a few years ago seeing a man on a rental e-scooter riding around Washington, D.C., with his child, maybe 2 or 3 years old, on his shoulders. It was a reminder of the need for better public education regarding these contraptions, not to mention common sense. Schofer said he sees the value in efficient conveyances like e-scooters, which can make it easier to navigate city streets. He also wonders about the risk involved, especially for young riders and tourists who may not be familiar with a town's layout and traffic patterns. 'You have a really cheap avenue to getting access to motorized transportation, and to young people who aren't licensed drivers, and to people of limited income, it's very appealing," he said. 'So how do you make this work?" 'A place in the transportation ecosystem' Dr. Ben Breyer, a professor at the University of California-San Francisco School of Medicine, said that's where city involvement comes in. Breyer spent 10 years at San Francisco's leading trauma center and conducted several studies on bicycle trauma. More recently, he collaborated in a widely cited UCSF study published last summer that found nationwide e-bike injuries nearly doubled and e-scooter injuries rose by more than 45% every year from 2017-2022. Despite that, Breyer's likes the potential for these vehicles. 'These kind of micromobility options do have a place in the transportation ecosystem," he said. 'They help keep cars off the road, they help decrease congestion, they help people make that final mile in their commute. I think we need more infrastructure to help support riders, and there may need to be some regulations on maximum speeds and these kind of things to help ensure folks ride safely." This article originally appeared on USA TODAY: Are electric scooters safe? Injuries, deaths raise concerns.
